Skip to content

Clinical efficacy of transcranial focused ultrasound stimulation intervention in depression

Clinical effect and mechanism of transcranial focused ultrasound stimulation on prefrontal cortex in patients with depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092046
Enrollment
Unknown
Registered
2024-11-08
Start date
2024-11-11
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

active stimulation group:Transcranial focused ultrasound active-stimulation
pseudo-stimulation group:Transcranial focused ultrasound pseudo-stimulation group

Sponsors

Affiliated Kangning Hospital of Ningbo University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-60 years old; 2. Depression was independently diagnosed by two psychiatrists according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); 3. Total score of HAMD-24 items >20 points; 4. Right-handed; 5. The patient's physical examination, medical history, vital signs, routine blood, urine and stool, liver and kidney function, electrolyte, electrocardiogram, electroencephalogram and other indicators were normal; 6. After fully understanding the safety of transcranial focused ultrasound, they are willing to actively cooperate with the treatment and have their informed consent signed by them and their family members.

Exclusion criteria

Exclusion criteria: 1. Age 60 years old; 2. Patients with a history of severe physical illness and depression caused by other psychoactive substances or non-dependent substances; 3. Patients with metal or electronic instruments, such as intracranial metal foreign bodies, cochlear implants, cardiac pacemakers, stents and other metal foreign bodies; 4. have the risk of seizures, previous craniocerebral disease, head trauma, alcoholism, EEG abnormalities, MRI evidence of brain structural abnormalities, or a family history of epilepsy; 5. Acute suicide victims; 6. People with psychotic symptoms who need to be combined with antipsychotic drugs; 7. Received ECT within 2 months before enrollment; 8. pregnant, breastfeeding or planning pregnancy during the trial; 9. Refusal to sign informed consent.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale (HAMD-24) ;Self-rating Depression Scale (SDS) ;Self-rating Anxiety Scale (SAS);Baker Suicide Ideation Scale Chinese version (BSI-CV) ;Neuropsychological Status Rating Scale (RBANS) ;

Secondary

MeasureTime frame
Electromyographic changes;Neuroelectrophysiological indicators;Hamilton Anxiety Scale (HAMA) ;

Countries

China

Contacts

Public ContactLi Xingxing

Affiliated Kangning Hospital of Ningbo University

290534201@qq.com+86 13857476641

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026